1 – 7 of 7
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes : Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2020
-
Mark
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
(
- Contribution to journal › Article
- 2018
-
Mark
Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny
(
- Contribution to journal › Letter
- 2017
-
Mark
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews
(
- Contribution to journal › Article
- 2016
-
Mark
Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
(
- Contribution to journal › Article